23andMe, the DNA testing company that turns saliva into in-depth genetic analysis, is raising $200 million in funding led by Sequoia Capital, sources close to the situation confirmed to Business Insider.
ADVERTISEMENT
23andMe gets $200 million in funding to bring its genetic testing to the masses
The company is worth $1.5 billion just months after overcoming hurdles from the US Food and Drug Administration.
ADVERTISEMENT
In 2013, the US Food and Drug Administration (FDA) barred the company from sending any data related to health to customers, over concerns that the company misrepresented genetic tests as medical advice. This prevented the company from providing information about things like a customer's risk for developing a certain type of cancer, which was one of its major products.
The company started selling the tests again in 2015 with the FDA's approval, and in April 2017, the FDA officially authorized 23andMe to market its direct-to-consumer tests for 10 different medical diseases and conditions, including Parkinson's and Alzheimer's.
23andMe declined to comment.
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
Studio Monkey in collaboration with Worldwide FM and Gilles Peterson launches initiative to support grassroot music communities
NexaScale marks one-year milestone with visionary initiatives empowering Africa's youth for the future of work
How Patrice Motsepe-backed GoSolr wants to solve South Africa's power crises
Harsh words for the World Bank from Uganda’s president at the meeting of African leaders
The artificial intelligence boom is real: why are more and more companies incorporating it into their operations?
The US and Uganda partner to combat a deadly enemy
See why ice is now pricier than bread and milk in this African country
8 ingenious tips to merge PDF files more efficiently